Cavitary pulmonary infarct in immunocompromised hosts

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pulmonary disease in immunocompromised patients is common, but cavitary lung disease is less common and is usually associated with a fungal or mycobacterial infection. Pulmonary embolism is a noninfectious cause of a cavitary pulmonary process. Pulmonary embolism causes infarction in fewer than 15% of cases, and only about 5% of infarctions cavitate. Herein we describe two cases of cavitary infarcts in immunocompromised patients and review the clinical aspects of pulmonary infarcts and cavitation. Cavitary pulmonary infarction has been reported only rarely in immunocompromised patients. It is a dangerous but treatable pulmonary disease that must be considered in the differential diagnosis of immunocompromised patients with lung disease.

Original languageEnglish (US)
Pages (from-to)66-68
Number of pages3
JournalMayo Clinic Proceedings
Volume70
Issue number1
StatePublished - 1995

Fingerprint

Immunocompromised Host
Lung Diseases
Lung
Pulmonary Embolism
Infarction
Pulmonary Infarction
Differential Diagnosis
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cavitary pulmonary infarct in immunocompromised hosts. / Morgenthaler, Timothy Ian; Ryu, Jay H; Utz, James P.

In: Mayo Clinic Proceedings, Vol. 70, No. 1, 1995, p. 66-68.

Research output: Contribution to journalArticle

@article{67621a77a4d54e2cbd6720c4fec4c42d,
title = "Cavitary pulmonary infarct in immunocompromised hosts",
abstract = "Pulmonary disease in immunocompromised patients is common, but cavitary lung disease is less common and is usually associated with a fungal or mycobacterial infection. Pulmonary embolism is a noninfectious cause of a cavitary pulmonary process. Pulmonary embolism causes infarction in fewer than 15{\%} of cases, and only about 5{\%} of infarctions cavitate. Herein we describe two cases of cavitary infarcts in immunocompromised patients and review the clinical aspects of pulmonary infarcts and cavitation. Cavitary pulmonary infarction has been reported only rarely in immunocompromised patients. It is a dangerous but treatable pulmonary disease that must be considered in the differential diagnosis of immunocompromised patients with lung disease.",
author = "Morgenthaler, {Timothy Ian} and Ryu, {Jay H} and Utz, {James P}",
year = "1995",
language = "English (US)",
volume = "70",
pages = "66--68",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Cavitary pulmonary infarct in immunocompromised hosts

AU - Morgenthaler, Timothy Ian

AU - Ryu, Jay H

AU - Utz, James P

PY - 1995

Y1 - 1995

N2 - Pulmonary disease in immunocompromised patients is common, but cavitary lung disease is less common and is usually associated with a fungal or mycobacterial infection. Pulmonary embolism is a noninfectious cause of a cavitary pulmonary process. Pulmonary embolism causes infarction in fewer than 15% of cases, and only about 5% of infarctions cavitate. Herein we describe two cases of cavitary infarcts in immunocompromised patients and review the clinical aspects of pulmonary infarcts and cavitation. Cavitary pulmonary infarction has been reported only rarely in immunocompromised patients. It is a dangerous but treatable pulmonary disease that must be considered in the differential diagnosis of immunocompromised patients with lung disease.

AB - Pulmonary disease in immunocompromised patients is common, but cavitary lung disease is less common and is usually associated with a fungal or mycobacterial infection. Pulmonary embolism is a noninfectious cause of a cavitary pulmonary process. Pulmonary embolism causes infarction in fewer than 15% of cases, and only about 5% of infarctions cavitate. Herein we describe two cases of cavitary infarcts in immunocompromised patients and review the clinical aspects of pulmonary infarcts and cavitation. Cavitary pulmonary infarction has been reported only rarely in immunocompromised patients. It is a dangerous but treatable pulmonary disease that must be considered in the differential diagnosis of immunocompromised patients with lung disease.

UR - http://www.scopus.com/inward/record.url?scp=0028899512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028899512&partnerID=8YFLogxK

M3 - Article

C2 - 7808055

AN - SCOPUS:0028899512

VL - 70

SP - 66

EP - 68

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -